A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris

The relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12 -week randomized, double-blind, placebo -controlled, clinical tr...

Full description

Bibliographic Details
Authors: Eguren C, Navarro-Blasco A, Corral-Forteza M, Reolid-Pérez A, Setó-Torrent N, García-Navarro A, Prieto-Merino D, Núñez-Delegido E, Sánchez-Pellicer P, Navarro-López V
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repository:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p17076
Online Access:https://fisabio.portalinvestigacion.com/publicaciones/17076
Access Level:Open access
Keyword:acne vulgaris
dermatology
clinical trial
clinical study
microbiota
probiotics
id ES_cb2c921d3a252ce0e2f1cfa992f41743
oai_identifier_str oai:fisabio.fundanetsuite.com:p17076
network_acronym_str ES
network_name_str España
repository_id_str
spelling A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne VulgarisEguren CNavarro-Blasco ACorral-Forteza MReolid-Pérez ASetó-Torrent NGarcía-Navarro APrieto-Merino DNúñez-Delegido ESánchez-Pellicer PNavarro-López Vacne vulgarisdermatologyclinical trialclinical studymicrobiotaprobioticsThe relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12 -week randomized, double-blind, placebo -controlled, clinical trial with patients aged 12 to 30 years with acne vulgaris was conducted. The study product was a capsule composed of the probiotic Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B). Patients with improvement in the Acne Global Severity Scale were 10/34 (29.41%) in the placebo group compared with 20/40 (50%) in the probiotic group ( p = 0.03). A significant reduction ( p = 0.03) in the number of non -inflammatory acne lesions was observed in the probiotic group (-18.60 [-24.38 to -12.82]) vs the placebo group (-10.54 [-17.43 to -3.66]). Regarding the number of total lesions, a reduction almost reaching statistical significance ( p = 0.06) was observed in the probiotic group (-27.94 [-36.35 to -19.53]) compared with the placebo group (-18.31 [-28.21 to -8.41]). In addition, patients with improvement attending the Global Acne Grading System were 7/34 (20.58%) in the placebo group vs 17/40 (42.50%) in the probiotic group ( p = 0.02). The number of adverse events was similar in both groups. The probiotic used in this study was effective and well tolerated, and it should be considered for acne vulgaris patients.ACTA DERMATO-VENEREOLOGICA2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/17076ACTA DERMATO-VENEREOLOGICAISSN: 00015555ISSNe: 16512057reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Inglésinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p170762026-06-11T12:45:17Z
dc.title.none.fl_str_mv A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
title A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
spellingShingle A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
Eguren C
acne vulgaris
dermatology
clinical trial
clinical study
microbiota
probiotics
title_short A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
title_full A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
title_fullStr A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
title_full_unstemmed A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
title_sort A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris
dc.creator.none.fl_str_mv Eguren C
Navarro-Blasco A
Corral-Forteza M
Reolid-Pérez A
Setó-Torrent N
García-Navarro A
Prieto-Merino D
Núñez-Delegido E
Sánchez-Pellicer P
Navarro-López V
author Eguren C
author_facet Eguren C
Navarro-Blasco A
Corral-Forteza M
Reolid-Pérez A
Setó-Torrent N
García-Navarro A
Prieto-Merino D
Núñez-Delegido E
Sánchez-Pellicer P
Navarro-López V
author_role author
author2 Navarro-Blasco A
Corral-Forteza M
Reolid-Pérez A
Setó-Torrent N
García-Navarro A
Prieto-Merino D
Núñez-Delegido E
Sánchez-Pellicer P
Navarro-López V
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv acne vulgaris
dermatology
clinical trial
clinical study
microbiota
probiotics
topic acne vulgaris
dermatology
clinical trial
clinical study
microbiota
probiotics
description The relevance of the gut microbiota in some skin inflammatory diseases, including acne vulgaris, has been emphasized. Probiotics could play a role in the modulation of the microbiota, improving the clinical course of this disease. A 12 -week randomized, double-blind, placebo -controlled, clinical trial with patients aged 12 to 30 years with acne vulgaris was conducted. The study product was a capsule composed of the probiotic Lacticaseibacillus rhamnosus (CECT 30031) and the cyanobacterium Arthrospira platensis (BEA_IDA_0074B). Patients with improvement in the Acne Global Severity Scale were 10/34 (29.41%) in the placebo group compared with 20/40 (50%) in the probiotic group ( p = 0.03). A significant reduction ( p = 0.03) in the number of non -inflammatory acne lesions was observed in the probiotic group (-18.60 [-24.38 to -12.82]) vs the placebo group (-10.54 [-17.43 to -3.66]). Regarding the number of total lesions, a reduction almost reaching statistical significance ( p = 0.06) was observed in the probiotic group (-27.94 [-36.35 to -19.53]) compared with the placebo group (-18.31 [-28.21 to -8.41]). In addition, patients with improvement attending the Global Acne Grading System were 7/34 (20.58%) in the placebo group vs 17/40 (42.50%) in the probiotic group ( p = 0.02). The number of adverse events was similar in both groups. The probiotic used in this study was effective and well tolerated, and it should be considered for acne vulgaris patients.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/17076
url https://fisabio.portalinvestigacion.com/publicaciones/17076
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ACTA DERMATO-VENEREOLOGICA
publisher.none.fl_str_mv ACTA DERMATO-VENEREOLOGICA
dc.source.none.fl_str_mv ACTA DERMATO-VENEREOLOGICA
ISSN: 00015555
ISSNe: 16512057
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419564881674240
score 15,228081

Similar Items